For Q2 2025, Aristotle Capital’s Global Equity Composite posted a total return of 9.58% gross of fees (9.45% net of fees), ...

Beta Bionics expects to have full results from the PK-PD bridging trial in the second half of 2025, which will inform the go-forward development strategy for the glucagon candidate. Estimated total ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results ...